Persistence of IgG response to SARS-CoV-2.
Persistence of IgG response to SARS-CoV-2.
复制标题
DOI：
10.1016/s1473-3099(20)30943-9
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Desombere I
中科院分区：
文献类型：
--
作者：
Duysburgh E;Mortgat L;Barbezange C;Dierick K;Fischer N;Heyndrickx L;Hutse V;Thomas I;Van Gucht S;Vuylsteke B;Ariën KK;Desombere I
对严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）的体液免疫反应的持续时间和保护能力知之甚少。在冰岛和美国的研究中，针对SARS-CoV-2的2种抗体在诊断后4个月内没有下降。然而，其他研究表明，抗体在3-4个月内迅速减弱。自2020年4月22日以来，我们一直在对来自比利时17家医院的850名卫生保健工作者进行有代表性的随访。每个月对参与者进行SARS-CoV-2的定量RT-PCR检测（RT-qPCR）和针对S1（刺突亚基1）蛋白的抗体的商业半定量ELISA检测（euroimmunoigg; Medizinische Labordiagnostika, l<e:2>贝克，德国），使用严格的制造商定义的检测结果阳性截止值（比例≥1.1;NCT04373889）。6、截至2020年9月底，已完成7轮测试。为了评估体液免疫反应的持续时间，我们记录了SARS-CoV-2血清阳性的卫生保健工作者血清中可检测到IgG的持续时间。至少需要连续两次阳性样本才能将参与者归类为血清阳性，而IgG消失的定义是在被归类为血清阳性后至少进行两次阴性检测。只有到过至少四个检测点并至少两次检测呈阳性的卫生保健工作者才被纳入本次评估。此外，我们对igg阳性样本进行了体外中和试验，测量了中和50% SARS-CoV-2 （NT50）所需的血清抗体滴度。
Little is known about the duration and protective capacity of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In studies from Iceland1 and the USA, 2 antibodies against SARS-CoV-2 did not decline within 4 months after diagnosis. However, other studies have reported rapid waning of antibodies within 3–4 months. 3–5 Since April 22, 2020, we have been following up a representative cohort of 850 health-care workers from 17 Belgian hospitals. Participants are tested on a monthly basis for the presence of SARS-CoV-2 with quantitative RT-PCR (RT-qPCR) and for antibodies targeting S1 (spike subunit 1) protein with a commercial semi-quantitative ELISA (Euroimmun IgG; Medizinische Labordiagnostika, Lübeck, Germany), using a stringent manufacturer-defined cut-off for having a positive test result (ratio≥ 1· 1; NCT04373889). 6 By the end of September, 2020, seven rounds of testing had been done. To assess the longevity of the humoral immune response, we recorded the duration of the presence of detectable IgG in the serum of health-care workers who were seropositive for SARS-CoV-2. At least two consecutive positive samples were needed to classify a participant as seropositive, whereas disappearance of IgG was defined as having at least two negative tests after having been classified as seropositive. Only health-care workers who attended at least four testing points and had at least two positive tests were included in this assessment. Additionally, we did in-vitro neutralisation tests on IgG-positive samples, measuring the serum titre of antibodies needed to neutralise 50% of SARS-CoV-2 (NT50).